Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29336990 | 0.83 | ALDH1A1 (0.44) | ALDH1A1GAADRD2DRD4DRD3 | |
| SCHEMBL7031444 | 0.81 | KCNH2 (0.51) | DRD2HTR2AHTR6KCNH2 | |
| SCHEMBL16763361 | 0.80 | ALDH1A1 (0.45) | ALDH1A1GAAHTR2AHTR6 | |
| SCHEMBL29337028 | 0.80 | DRD2 (0.43) | ALDH1A1GAADRD2DRD4DRD3 | |
| SCHEMBL7026019 | 0.78 | KCNH2 (0.66) | DRD2HTR2AHTR6KCNH2 | |
| SCHEMBL29337009 | 0.77 | ALDH1A1 (0.47) | KMT2AALDH1A1GAALMNAHTR6 | |
| SCHEMBL27249952 | 0.75 | L3MBTL1 (0.49) | KMT2AALDH1A1DRD2HTR2ALMNA | |
| SCHEMBL29338313 | 0.74 | ALDH1A1 (0.40) | KMT2AALDH1A1GAACYP2D6LMNA | |
| SCHEMBL27154163 | 0.74 | GPR119 (0.47) | ALDH1A1GAAMAPT | |
| SCHEMBL29337104 | 0.65 | ALDH1A1 (0.42) | KMT2AALDH1A1GAAMAPTHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239801-A1 | PYRIMIDO[5,4,D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239801-A1 | PYRIMIDO[5,4,D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | NRAS, BRAF, KRAS | KMT2A 2665/4885ALDH1A1 1786/4885GAA 2372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.